- Home
- MUJ vs CAPR Comparison
MUJ vs CAPR Comparison
Compare MUJ & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- CAPR
- Stock Information
- Founded
- MUJ 1998
- CAPR 2005
- Country
- MUJ United States
- CAPR United States
- Employees
- MUJ N/A
- CAPR N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MUJ Finance
- CAPR Health Care
- Exchange
- MUJ Nasdaq
- CAPR Nasdaq
- Market Cap
- MUJ 602.6M
- CAPR 578.4M
- IPO Year
- MUJ N/A
- CAPR N/A
- Fundamental
- Price
- MUJ $11.36
- CAPR $14.06
- Analyst Decision
- MUJ
- CAPR Strong Buy
- Analyst Count
- MUJ 0
- CAPR 7
- Target Price
- MUJ N/A
- CAPR $39.29
- AVG Volume (30 Days)
- MUJ 108.0K
- CAPR 1.1M
- Earning Date
- MUJ 01-01-0001
- CAPR 02-27-2025
- Dividend Yield
- MUJ 4.36%
- CAPR N/A
- EPS Growth
- MUJ N/A
- CAPR N/A
- EPS
- MUJ N/A
- CAPR N/A
- Revenue
- MUJ N/A
- CAPR $23,228,045.00
- Revenue This Year
- MUJ N/A
- CAPR N/A
- Revenue Next Year
- MUJ N/A
- CAPR $74.85
- P/E Ratio
- MUJ N/A
- CAPR N/A
- Revenue Growth
- MUJ N/A
- CAPR 65.33
- 52 Week Low
- MUJ $9.74
- CAPR $3.52
- 52 Week High
- MUJ $11.70
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- MUJ 53.96
- CAPR 48.54
- Support Level
- MUJ $11.21
- CAPR $12.31
- Resistance Level
- MUJ $11.34
- CAPR $16.17
- Average True Range (ATR)
- MUJ 0.10
- CAPR 0.82
- MACD
- MUJ 0.05
- CAPR 0.11
- Stochastic Oscillator
- MUJ 88.64
- CAPR 45.34
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.